- Home
- PETZ vs IMRN Comparison
PETZ vs IMRN Comparison
Compare PETZ & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETZ
- IMRN
- Stock Information
- Founded
- PETZ 2002
- IMRN 1994
- Country
- PETZ China
- IMRN Australia
- Employees
- PETZ N/A
- IMRN N/A
- Industry
- PETZ Steel/Iron Ore
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- PETZ Industrials
- IMRN Health Care
- Exchange
- PETZ Nasdaq
- IMRN Nasdaq
- Market Cap
- PETZ 9.3M
- IMRN 9.2M
- IPO Year
- PETZ 2017
- IMRN N/A
- Fundamental
- Price
- PETZ $1.01
- IMRN $1.87
- Analyst Decision
- PETZ
- IMRN Strong Buy
- Analyst Count
- PETZ 0
- IMRN 1
- Target Price
- PETZ N/A
- IMRN $5.00
- AVG Volume (30 Days)
- PETZ 5.6K
- IMRN 26.3K
- Earning Date
- PETZ 04-28-2025
- IMRN 09-08-2025
- Dividend Yield
- PETZ N/A
- IMRN N/A
- EPS Growth
- PETZ N/A
- IMRN N/A
- EPS
- PETZ 0.26
- IMRN N/A
- Revenue
- PETZ $563,726.00
- IMRN $4,048,286.00
- Revenue This Year
- PETZ N/A
- IMRN N/A
- Revenue Next Year
- PETZ N/A
- IMRN N/A
- P/E Ratio
- PETZ $4.94
- IMRN N/A
- Revenue Growth
- PETZ 74664.72
- IMRN 82.90
- 52 Week Low
- PETZ $0.65
- IMRN $1.50
- 52 Week High
- PETZ $1.74
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- PETZ 51.04
- IMRN 58.63
- Support Level
- PETZ $0.95
- IMRN $1.70
- Resistance Level
- PETZ $1.03
- IMRN $1.78
- Average True Range (ATR)
- PETZ 0.07
- IMRN 0.10
- MACD
- PETZ -0.00
- IMRN 0.01
- Stochastic Oscillator
- PETZ 60.95
- IMRN 77.50
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling pet food and restaurant operations. The company has two operating segments, which include Petfood sales and the Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.